AU2007256717B2 - HIV-1 Clade A consensus sequences, antigens, and transgenes - Google Patents

HIV-1 Clade A consensus sequences, antigens, and transgenes Download PDF

Info

Publication number
AU2007256717B2
AU2007256717B2 AU2007256717A AU2007256717A AU2007256717B2 AU 2007256717 B2 AU2007256717 B2 AU 2007256717B2 AU 2007256717 A AU2007256717 A AU 2007256717A AU 2007256717 A AU2007256717 A AU 2007256717A AU 2007256717 B2 AU2007256717 B2 AU 2007256717B2
Authority
AU
Australia
Prior art keywords
hiv
clade
sequences
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007256717A
Other languages
English (en)
Other versions
AU2007256717A1 (en
Inventor
Kalpana Gupta
Nicholas Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International AIDS Vaccine Initiative Inc
Original Assignee
International AIDS Vaccine Initiative Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International AIDS Vaccine Initiative Inc filed Critical International AIDS Vaccine Initiative Inc
Publication of AU2007256717A1 publication Critical patent/AU2007256717A1/en
Application granted granted Critical
Publication of AU2007256717B2 publication Critical patent/AU2007256717B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2007256717A 2006-06-02 2007-06-04 HIV-1 Clade A consensus sequences, antigens, and transgenes Ceased AU2007256717B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81081606P 2006-06-02 2006-06-02
US60/810,816 2006-06-02
PCT/US2007/070321 WO2007143606A2 (en) 2006-06-02 2007-06-04 Hiv-1 clade a consensus sequences, antigens, and transgenes

Publications (2)

Publication Number Publication Date
AU2007256717A1 AU2007256717A1 (en) 2007-12-13
AU2007256717B2 true AU2007256717B2 (en) 2013-06-20

Family

ID=38802278

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007256717A Ceased AU2007256717B2 (en) 2006-06-02 2007-06-04 HIV-1 Clade A consensus sequences, antigens, and transgenes

Country Status (8)

Country Link
US (2) US8119144B2 (https=)
EP (2) EP2399602B1 (https=)
JP (1) JP2009539353A (https=)
AU (1) AU2007256717B2 (https=)
CA (1) CA2654324A1 (https=)
DK (2) DK2029168T3 (https=)
ES (2) ES2396915T3 (https=)
WO (1) WO2007143606A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
US20160256539A1 (en) * 2013-11-14 2016-09-08 The Trustees Of The University Of Pennsylvania HIV-1 ENV DNA Vaccine Plus Protein Boost Delivered by EP Expands B- and T-Cell Response and Neutralizing
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047955A2 (en) * 1999-12-23 2001-07-05 Medical Research Council Improvements in or relating to immune responses to hiv

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
PT799058E (pt) 1994-12-24 2003-11-28 Univ Cambridge Tech Melhoramentos na funcao endometrica ou com ela relacionados
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US20020136722A1 (en) 1997-06-18 2002-09-26 Heath Andrew William Vaccination method
CA2302522C (en) 1997-08-29 2010-08-17 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
JP2004507231A (ja) 2000-06-15 2004-03-11 アメリカ合衆国 免疫応答を向上させるための、ｇｍ−ｃｓｆを発現する組換え非−複製性ウィルスおよびその使用
IT1318103B1 (it) 2000-07-03 2003-07-23 Nuovo Pignone Spa Sistema di connessione tra un ugello di bassa pressione ed untransition duct in una turbina a gas
BRPI0414443A (pt) * 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
WO2005047483A2 (en) * 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047955A2 (en) * 1999-12-23 2001-07-05 Medical Research Council Improvements in or relating to immune responses to hiv

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Howard, T. et al. 1996 AIDS RES. HUM RETRO., Vol. 12, No. 15, pp. 1413-1425 *
Malm, M. et al. 2005 VIRAL IMMUNOL., Vol. 18, No.4, pp. 678-688 *
Nkolola, J. et al. 2004 GENE THER., Vol. 11, pp. 1068-1080 *

Also Published As

Publication number Publication date
EP2029168B1 (en) 2012-10-03
WO2007143606A2 (en) 2007-12-13
US20080089909A1 (en) 2008-04-17
JP2009539353A (ja) 2009-11-19
EP2399602B1 (en) 2014-11-26
EP2029168A2 (en) 2009-03-04
AU2007256717A1 (en) 2007-12-13
CA2654324A1 (en) 2007-12-13
WO2007143606A9 (en) 2008-02-14
EP2399602A1 (en) 2011-12-28
EP2029168A4 (en) 2010-10-27
ES2528951T3 (es) 2015-02-13
US8119144B2 (en) 2012-02-21
DK2029168T3 (da) 2013-01-14
DK2399602T3 (en) 2015-02-23
US8735542B2 (en) 2014-05-27
US20120219577A1 (en) 2012-08-30
WO2007143606A3 (en) 2008-11-13
ES2396915T3 (es) 2013-03-01

Similar Documents

Publication Publication Date Title
Ramakrishna et al. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization
US8586056B2 (en) HIV-1 envelope glycoprotein
US20090227658A1 (en) Methods and compositions for immunization against hiv
US8735542B2 (en) HIV-1 clade a consensus sequences, antigens, and transgenes
Nkolola et al. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa
AU2008318677A1 (en) Antigen-antibody complexes as HIV-1 vaccines
EP2848937A1 (en) Methods of identifying novel HIV-1 immunogens
US20080306244A1 (en) Renta: an HIV immunogen and uses thereof
US20080274992A1 (en) Recombinant modified ankara viral hiv-1 vaccines
EP2679596B1 (en) HIV-1 env glycoprotein variant
US20080102073A1 (en) Antigen-Antibody Complexes as HIV-1 Vaccines
Doria‐Rose et al. Multigene DNA prime‐boost vaccines for SHIV89. 6P
US8105600B2 (en) Method of inducing high-titer neutralizing antibody responses in a host by administering immune complexes comprising anti-HIV-1 Env antibodies and the HIV-1 Env
WO2016065252A2 (en) Native trimeric env immunogen design
WO2017007646A1 (en) Hiv-1 clade c envelope glycoproteins
Baumeister et al. Prospects for an HIV vaccine: Conventional approaches and DNA immunization

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired